Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III perioperative Becotatug vedotin + pucotenlimab vs pucotenlimab in resectable locally advanced EGFR-positive head and neck squamous cell carcinoma
ChiCTR2600125057Phase 3Not yet recruiting
- Sponsor
- The Fifth Affiliated Hospital of Sun Yat-sen University
- Start
- May 2026
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised trial in head and neck squamous cell carcinoma (HNSCC) comparing Becotatug vedotin + pucotenlimab perioperative with Control: pucotenlimab perioperative (2 arms). Primary endpoint: 3-year event-free survival rate. Planned start May 2026; status: not yet recruiting.
02
Drugs
becotatug vedotinpucotenlimab
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on ChiCTR2600125057.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600125057.